China's bio-pharmaceutical industry has entered a period of innovation and activity
Biomedicine is a large gap between China and developed countries. Statistics show that the global market for innovative drugs is nearly $600 billion, compared with less than $10 billion in China. However, with the launch of national drug regulatory reform in recent years, China's biomedicine industry has gradually entered the fast lane, attracting the attention of many investors.
Founded only three years ago, nasdaq successfully listed on nasdaq. Shares rose 55 per cent on their debut, with a market capitalisation of $1.3bn. The speed of the listing, which has only been seen in the Internet industry, appears in a new drug development company in zhangjiang, Shanghai.
At a recent public communication conference, du ying, chairman of reding medicine, said that the current research and development of new drugs in China has entered the spring. With independent r&d and transnational cooperation, reding is committed to developing products that meet the needs of domestic patients as soon as possible in the fields of tumor, anti-infection and autoimmunity.
Before the ding, the drug Ming Kantian group's drug - Ming life was listed in Hong Kong this year. According to the prospectus, the drug is mainly engaged in the development of biological agents and is currently building the world's largest production facility for disposable bioreactors.
In addition to listing, mergers and acquisitions activity in the health sector has also maintained a high degree of heat. Jiangsu tricell group from the beginning of the $819 million acquisition of a biological pharmaceutical companies in the United States, in the year to October fosun medicine for $1.091 billion to complete acquisition of India's grand pharmaceutical, Chinese pharmaceutical enterprise m&a records constantly refreshed, targeting with the core technology of targets.
Capital market movements frequently reflect the vitality of domestic biomedical innovation. Behind the boom is the support of three key forces:
The state drug regulatory reform was deepened. "This year's drug regulatory reform is unprecedented in strength and depth, surpassing the progress of the past few years." Song ruilin, executive director of the China association for the promotion of medical innovation, said.
The reform of other departments has also been actively promoted, and formed a synergy with the reform of drug administration. Released recently, Shanghai zhangjiang medicine valley in the inspection and quarantine inspection of the animal and plant quarantine certificate of the exporting country or region of from the list of the third edition, about 18 types of plant and animal products exempted from inspection and quarantine certificate abroad, nine products belong to the life science research institute of biological materials.
"The inspection and quarantine reform will solve some of the problems of 'slow progress' and 'difficulty' in some biological materials, benefiting many scientific research institutions and pharmaceutical r&d enterprises in zhangjiang and Shanghai." Shanghai inspection and quarantine bureau mobile plant everywhere changbai zhanghong said.
Key pharmaceutical enterprises have accumulated thin hair. Pharmaceutical research and development is a typical activity with long period and large investment. After years of focus and efforts, a batch of new drugs of domestic key pharmaceutical companies are about to enter the "harvest time".
Taking a-shares as an example, fosun pharmaceutical said that there are currently 11 global clinical batches of 8 products in the area of tumor and autoimmune diseases. In the first half of this year, the company invested a total of 780 million yuan in r&d, a 60% year-on-year increase, and basically formed a benign development trend with innovative drugs applied every year.
Enthusiasm for venture capital soared. The high technology and high input characteristics of biomedical research and development are very compatible with the orientation of venture capital. Chinese pharmaceutical companies, such as baiji shenzhou and reding pharmaceuticals, which have been listed on nasdaq, have venture capitalists behind them.
"Before 2015, the hot spots in the pharmaceutical investment community were generic drugs and biosimilars. This year, money is flowing to innovative drugs, and many projects have been invested tens or hundreds of millions of yuan in A round. Investment in innovative drugs is almost "summer". Yuan he origin fund partner zhao qun said.
